Last reviewed · How we verify
Placenta Derived Mesenchymal Stem Cell
Placenta Derived Mesenchymal Stem Cell, marketed by the Affiliated Hospital of Jiangsu University, holds a unique position in the regenerative medicine sector. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and potential competitive advantage. However, the lack of detailed revenue data and primary trial results poses a primary risk, making it challenging to assess the drug's commercial and clinical performance.
At a glance
| Generic name | Placenta Derived Mesenchymal Stem Cell |
|---|---|
| Also known as | Mesenchymal Stromal Cells (MSCs) |
| Sponsor | Affiliated Hospital of Jiangsu University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Novel Therapeutic Treatment of Pyoderma Gangrenosum (PHASE4)
- A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) (PHASE1)
- Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19) (PHASE1)
- Human Placenta Mesenchymal Stem Cells Derived Exosomes Injection for Treatment of Complex Anal Fistula (PHASE2)
- Spine Unit Modelling Coupled With hIgh Throughput Analysis (SUIT)
- Effect of PMSCs and Their Secretome for the Treatment of GvHD (PHASE3)
- Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis (PHASE1)
- Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |